(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Novo Integrated and Northrop Grumman: Breakthrough Mega Deals

September 29th, 2023

Shares of Novo Integrated Sciences, Inc. (Nasdaq: NVOS) surged by more than 100% in after-hours trading following the company's announcement of a significant development. Novo and Blacksheep Trust have finalized a One Billion Dollar Master Collateral. Read more

Earnings Reactions: NIKE and BlackBerry Post Mixed Results

September 28th, 2023

NIKE, Inc. (NYSE: NKE), a prominent sportswear and athletic equipment company, reported first-quarter fiscal 2024 earnings of $0.94 per share, surpassing the consensus EPS estimate of $0.74. Quarterly revenues for the company amounted to $12.9 billio. Read more

Setback for BrainStorm Cell Therapeutics; Accenture Posts Mixed Results

September 28th, 2023

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a biotechnology company that specializes in developing innovative stem cell therapies for neurodegenerative diseases, faced a setback as the U.S. Food and Drug Administration's Cellular, Tissue, and G. Read more

Momentum Builds: Gritstone bio's BARDA Contract; Peloton's Lululemon 5-Year Pact

September 28th, 2023

Shares of Gritstone bio, Inc. (Nasdaq: GRTS) soared over 40% in after-hours trading  following the company's announcement of an up to $433 million contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). The contra. Read more

Micron Technology Beats Estimates, Guidance Disappoints

September 27th, 2023

Micron Technology, Inc. (Nasdaq: MU), a renowned semiconductor company, reported a loss of $(1.07) per share for the fourth quarter of fiscal 2023, better than the consensus estimate loss of $(1.18). The company's quarterly revenues reached $4.01 bil. Read more

FTC Sues Amazon for Illegally Maintaining Monopoly Power

September 27th, 2023

Amazon’s ongoing pattern of illegal conduct blocks competition, allowing it to wield monopoly power to inflate prices, degrade quality, and stifle innovation for consumers and businesses Washington D.C. / CRWE PRESS RELEASE / September 26, 2. Read more

Bullish View On Blink Charging; Pfizer Deal Boosts Ginkgo Bioworks

September 27th, 2023

UBS has initiated coverage on Blink Charging Co. (Nasdaq: BLNK), a leading provider of electric vehicle charging services, with a Buy rating and a price target of $7. With $BLNK closing at $2.93 on Tuesday, the price target suggests a significant . Read more

Galecto Seeks Strategic Options; Palantir Lands $250M Army Contract

September 26th, 2023

Shares of Galecto, Inc. (Nasdaq: GLTO) surged by more than 30% in after-hous trading following the company's announcement of a comprehensive review of its business operations. Galecto aims to explore strategic alternatives focused on maximizing sh. Read more

MillerKnoll Beats Wall Street Forecasts; Rocket Lab Lowers Outlook

September 26th, 2023

MillerKnoll, Inc. (Nasdaq: MLKN) reported robust first-quarter fiscal 2024 earnings, coming in at $0.37 per share, surpassing the consensus EPS estimate of $0.21. The company also exceeded revenue expectations, with quarterly sales reaching $917.70 m. Read more

PWS Study Data Boost Soleno Therapeutics; Bullish View on Fisker

September 26th, 2023

Shares of Soleno Therapeutics, Inc. (Nasdaq: SLNO) soared over 300% in pre-market trading following the release of positive top-line results from Study C602.  The study, which focused on the long-term treatment of Prader-Willi syndrome (PWS) . Read more